CN110573162A - 靶向前列腺素e2及其受体的药物与应用 - Google Patents

靶向前列腺素e2及其受体的药物与应用 Download PDF

Info

Publication number
CN110573162A
CN110573162A CN201880028018.9A CN201880028018A CN110573162A CN 110573162 A CN110573162 A CN 110573162A CN 201880028018 A CN201880028018 A CN 201880028018A CN 110573162 A CN110573162 A CN 110573162A
Authority
CN
China
Prior art keywords
pge2
vascular
receptor
injury
functional fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880028018.9A
Other languages
English (en)
Inventor
王淼
郝会峰
胡昇
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fuwai Hospital of CAMS and PUMC
Original Assignee
Fuwai Hospital of CAMS and PUMC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fuwai Hospital of CAMS and PUMC filed Critical Fuwai Hospital of CAMS and PUMC
Publication of CN110573162A publication Critical patent/CN110573162A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明涉及一种调节对象中血管重构的方法，包括给予对象有效量的能够上调PGE2受体EP4和/或EP2信号通路信号传导活性的物质；本发明还提供了能够上调PGE2受体EP4和/或EP2信号通路信号传导活性的物质在制备用于调节对象中血管重构的药物中的应用；本发明还提供了用于调节对象中血管重构的制品，其包含能够上调PGE2受体EP4和/或EP2信号通路信号传导活性的物质。

Description

PCT国内申请，说明书已公开。

Claims (18)

  1. PCT国内申请，权利要求书已公开。
CN201880028018.9A 2017-04-28 2018-04-28 靶向前列腺素e2及其受体的药物与应用 Pending CN110573162A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710293360 2017-04-28
CN2017102933609 2017-04-28
PCT/CN2018/085035 WO2018196870A1 (zh) 2017-04-28 2018-04-28 靶向前列腺素e2及其受体的药物与应用

Publications (1)

Publication Number Publication Date
CN110573162A true CN110573162A (zh) 2019-12-13

Family

ID=63919464

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880028018.9A Pending CN110573162A (zh) 2017-04-28 2018-04-28 靶向前列腺素e2及其受体的药物与应用

Country Status (2)

Country Link
CN (1) CN110573162A (zh)
WO (1) WO2018196870A1 (zh)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1148394A (zh) * 1994-03-23 1997-04-23 小野药品工业株式会社 前列腺素e受体
JP2006522136A (ja) * 2003-04-02 2006-09-28 ネックスメド ホールディングス インコーポレイテッド プロスタグランジン組成物および血管痙攣の治療のためのその使用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANDERS LUNDEQUIST等: "Prostaglandin E2 Exerts Homeostatic Regulation of Pulmonary Vascular Remodeling in Allergic Airway Inflammation", 《THE JOURNAL OF IMMUNOLOGY》 *
HUIFENG HAO等: "Protective Role of mPGES-1 (Microsomal Prostaglandin E Synthase-1)-Derived PGE2 (Prostaglandin E2) and the Endothelial EP4 (Prostaglandin E Receptor) in Vascular Responses to Injury", 《ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY》 *

Also Published As

Publication number Publication date
WO2018196870A1 (zh) 2018-11-01

Similar Documents

Publication Publication Date Title
Liu et al. SIRT1 activation attenuates cardiac fibrosis by endothelial-to-mesenchymal transition
Song et al. Down-regulation of microRNA-320 suppresses cardiomyocyte apoptosis and protects against myocardial ischemia and reperfusion injury by targeting IGF-1
Yoon et al. The opposing effects of CCN2 and CCN5 on the development of cardiac hypertrophy and fibrosis
Yin et al. SDF-1α involved in mobilization and recruitment of endothelial progenitor cells after arterial injury in mice
US9808501B2 (en) Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
Vinh et al. Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice
WO2011053822A2 (en) Notch inhibition in the treatment and prevention of obesity and metabolic syndrome
Guo et al. 1, 25-Dihydroxyvitamin D attenuates diabetic cardiac autophagy and damage by vitamin D receptor-mediated suppression of FoxO1 translocation
WO2015035199A1 (en) Neem compositions used for the treatment of cancer
US7959918B2 (en) Methods for treating vascular disease
WO2015025956A1 (ja) 心筋障害治療用薬剤組成物、心筋障害予防用薬剤組成物、心不全治療用薬剤組成物、心不全予防用薬剤組成物、心筋障害又は心不全を治療又は予防する方法、ｍｆｇ－ｅ８、ｍｆｇ－ｅ８の使用、及び心筋障害又は心不全を治療又は予防する化合物のスクリーニング方法
Zhang et al. In vivo knockdown of nicotinic acetylcholine receptor α1 diminishes aortic atherosclerosis
Yin et al. Tongxinluo attenuates myocardiac fibrosis after acute myocardial infarction in rats via inhibition of endothelial‐to‐mesenchymal transition
Bus et al. Endoglin Mediates Vascular Endothelial Growth Factor-A–Induced Endothelial Cell Activation by Regulating Akt Signaling
JPWO2006134692A1 (ja) Ｒａｍｐ２を標的とする血管構造の安定化剤及び血管新生剤
JPWO2006134692A6 (ja) Ｒａｍｐ２を標的とする血管構造の安定化剤及び血管新生剤
Moreira et al. Synthetic apolipoprotein AI mimetic peptide 4F protects hearts and kidneys after myocardial infarction
US8741299B2 (en) Method for treating pathologies associated with hypoxia using MIF inhibitors
US20110275571A1 (en) Kv1.3 channel blocking substances for the treatment of diseases associated with intimal hyperplasia
He et al. Krüppel-like factor 15 modulates CXCL1/CXCR2 signaling-mediated inflammatory response contributing to angiotensin II-induced cardiac remodeling
Ichihara et al. Inhibition of ischemia-induced angiogenesis by benzo [a] pyrene in a manner dependent on the aryl hydrocarbon receptor
Chen et al. Glucocorticoid ameliorates early cardiac dysfunction after coronary microembolization and suppresses TGF-β1/Smad3 and CTGF expression
Chen et al. Synergic effect of combined cyclosporin and melatonin protects the brain against acute ischemic reperfusion injury
US10272133B2 (en) Compositions and methods for treating and preventing hyperlipidemia, fatty liver, atherosclerosis and other disorders associated with metabolic syndrome
CN110573162A (zh) 靶向前列腺素e2及其受体的药物与应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20191213